A Phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer

L. G. Feun, K. R. Reddy, J. M. Yrizarry, N. Savaraj, Jorge J. Guerra, R. K. Purser, S. Waldman, J. U. Levi, F. Moffatt, L. Morrell, A. S. Livingstone, B. Ardalan, P. Benedetto

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Twenty patients with either unresectable primary hepatocellular carcinoma or hepatic metastases were entered into a chemoembolization program with cisplatin and lipiodol; 19 patients were evaluable for response. Doses of cisplatin ranged from 40 to 100 mg/m2. Toxicity was tolerable and reversible and included abdominal pain, transient elevation in serum creatinine, serum bilirubin, and serum transaminases. Less common side effects include fever, ascites or pleural effusion, and hiccups. Two of four patients with ocular melanoma had partial responses. Duration of response was 10 and 11 months. Among 8 patients with unresectable hepatoma, 2 patients had partial response for 10+ and 13 months, 2 had minor response for 2 months and 4+ months, 1 patient had stable disease for 5+ months, and 3 patients failed to respond. Of the six colon cancer patients treated, one had a partial response in the liver, but developed progressive nodal disease, and another patient had a partial response for 3 months. Chemoembolization of the liver with cisplatin and lipiodol is feasible and doses of cisplatin at least 100 mg/m2 are tolerable. Antitumor activity in metastatic ocular melanoma is encouraging but requires further study.

Original languageEnglish (US)
Pages (from-to)405-410
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number5
StatePublished - Jan 1 1994

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A Phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer'. Together they form a unique fingerprint.

Cite this